OrbiMed’s Bolt Biotherapeutics BOLT Stock Holding History

OrbiMed’s Portfolio BOLT Stock Details BOLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-77,050	Closed	-$2.16M	–	118
2024 Q1	$2.16M	Hold	77,050	–	–	0.04%	103
2023 Q4	$1.73M	Hold	77,050	–	–	0.03%	99
2023 Q3	$1.6M	Hold	77,050	–	–	0.03%	116
2023 Q2	$1.97M	Hold	77,050	–	–	0.04%	116
2023 Q1	$2.14M	Buy	77,050 +38,497	+100%	+$1.13M	0.04%	112
2022 Q4	$1M	Hold	38,553	–	–	0.02%	110
2022 Q3	$1.14K	Buy	+38,553	New	+$1.6M	0.02%	126

Other funds holding BOLT

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2B AUM 117.41% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return